Regenera Pharma Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- Drug: RPh201 Cohort AOther: Placebo Cohort ADrug: RPh201 Cohort BOther: Placebo Cohort B
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 165
- Registration Number
- NCT03547206
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Neuro-Eye Clinical Trials, Inc., Houston, Texas, United States
🇺🇸New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
- Conditions
- Mild to Moderate Dementia Due to Alzheimer's DiseaseWith or Without Coexisting Cerebrovascular Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 83
- Registration Number
- NCT03462121
- Locations
- 🇨🇦
Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada
🇨🇦Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇨🇦Gerontion Research Inc., The Center for Memory & Aging, Toronto, Ontario, Canada
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
- Conditions
- Non-arteritic Ischemic Optic NeuropathyOptic Nerve Injuries
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT02045212
- Locations
- 🇮🇱
Ophthalmology Department, Western Galilee-Nahariya Medical Center, Nahariya, Israel
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
- Conditions
- Moderate to Severe Alzheimer PatientsHealthy Volunteers
- Interventions
- Drug: PlaceboDrug: RPh201, botanical drug product
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT01513967
- Locations
- 🇨🇦
Kendle Early Stage - Toronto, Toronto, Ontario, Canada
🇨🇦Toronto Memory Program, Toronto, Ontario, Canada
Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn
- Conditions
- Second Degree Burn Less Than 5%TBSAPartial Thickness Burn
- Interventions
- Drug: RPh201, botanical drug product
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Regenera Pharma Ltd
- Registration Number
- NCT01455480
- Locations
- 🇮🇱
Clinic of the The Burn Unit, The Department of Plastic & Reconstructive Surgery and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center, Tel Hashomer, Israel
Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds
- Conditions
- Chronic Wound
- Interventions
- Drug: RPh201, botanical drug product
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT01429519
- Locations
- 🇮🇱
High Risk Foot Clinic - Maccabi Health Services, Tel-Aviv, Israel